The average P/E for biotech was 24.6 in 3Q13 compared to 14.5 for big pharma, with both benchmarks affected by robust price moves among several of the profit-making companies used in the calculations.

Biotech's average P/E was up 16% from 2Q13, helped by the addition of Regeneron Pharmaceuticals Inc.